Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Genitourinary 1

Conditions

Carcinoma, Renal Cell 18Neoplasms 12Kidney Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 4Neoplasm Metastasis 4Gastrointestinal Stromal Tumors 4Carcinoma, Non-Small-Cell Lung 4Solid Tumors 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Leukemia, Myeloid, Acute 3Glioblastoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Primary Myelofibrosis 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Glioma 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Brain Neoplasms 2Advanced Cancer 2

Interventions

lutetium Lu 177 dotatate 2Sunitinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Everolimus 2sargramostim 1sapanisertib 1pentetreotide 1pasireotide 1napabucasin 1montanide ISA 51 1irinotecan sucrosofate 1incomplete Freund's adjuvant 1fludarabine phosphate 1aflibercept 1Taxes 1Sorafenib 1Salts 1Paclitaxel 1Oxaliplatin 1Octreotide 1Leucovorin 1Irinotecan 1Interleukin-13 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Adenoma, Islet Cell × Sunitinib × Clear all
NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT05800106 2023-04-10

A Bioequivalence Study of Sunitinib Malate Capsules.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Completed
24 enrolled
GastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Adenoma, Islet Cell, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡